Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
August 17, 2021
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer
Lisa A Kachnic, Kathryn A Winter, Robert J Myerson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 25, 2015
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408
Daniel J Krauss, Chen Hu, Jean-Paul Bahary, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2020
Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617
Maria Thor, Joseph O Deasy, Chen Hu, et al.
JAMA Oncology
|
June 27, 2024
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial
Stephen G Chun, Chen Hu, Ritsuko U Komaki, et al.
The Lancet. Oncology
|
January 21, 2015
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D Bradley, Rebecca Paulus, Ritsuko Komaki, et al.
JAMA Oncology
|
November 26, 2015
Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial
Benjamin Movsas, Chen Hu, Jeffrey Sloan, et al.
Cancers
|
December 24, 2021
Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617
Jian-Yue Jin, Chen Hu, Ying Xiao, et al.
American Journal of Clinical Oncology
|
November 22, 2022
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529
Jordan R Kharofa, Greg Yothers, Lisa A Kachnic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
Stephen G Chun, Chen Hu, Hak Choy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2019
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
Jeffrey D Bradley, Chen Hu, Ritsuko R Komaki, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
International Journal of Radiation Oncology, Biology, Physics
|
August 17, 2021
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer
Lisa A Kachnic, Kathryn A Winter, Robert J Myerson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 25, 2015
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408
Daniel J Krauss, Chen Hu, Jean-Paul Bahary, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2020
Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617
Maria Thor, Joseph O Deasy, Chen Hu, et al.
JAMA Oncology
|
June 27, 2024
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial
Stephen G Chun, Chen Hu, Ritsuko U Komaki, et al.
The Lancet. Oncology
|
January 21, 2015
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D Bradley, Rebecca Paulus, Ritsuko Komaki, et al.
JAMA Oncology
|
November 26, 2015
Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial
Benjamin Movsas, Chen Hu, Jeffrey Sloan, et al.
Cancers
|
December 24, 2021
Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617
Jian-Yue Jin, Chen Hu, Ying Xiao, et al.
American Journal of Clinical Oncology
|
November 22, 2022
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529
Jordan R Kharofa, Greg Yothers, Lisa A Kachnic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
Stephen G Chun, Chen Hu, Hak Choy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2019
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
Jeffrey D Bradley, Chen Hu, Ritsuko R Komaki, et al.
Page
of 4